

2026년 표적치료연구회 춘계학술대회



What are the evidence-based next-line management strategies for advanced lung cancer after first-line therapy?

| 일시 | 2026년 3월 14일(토) | 장소 | 전북대병원 지하 1층 모약홀

09:30-10:45	등록	
10:45-11:00	개회사	장윤수 (표적치료연구회 회장)
	축사	우흥균 (대한폐암학회 이사장)
	프로그램소개	엄상원 (표적치료연구회 학술위원장)
11:00-12:15	Session 1: NSCLC without actionable genetic alterations after first-line chemo-immunotherapy	좌장 김희정 (건국의대)
11:00-11:25	Current landscape of second-line treatment	최수인 (고려의대)
11:25-11:50	How to overcome primary resistance to first-line chemo-immunotherapy	김규연 (가톨릭의대)
11:50-12:15	Novel therapeutic options and treatment sequencing strategies	유우경 (인하의대)
12:15-13:10	Lunch	
13:10-14:00	Session 2: NSCLC with actionable genetic alterations beyond first-line TKIs	좌장 박순호 (계명의대)
13:10-13:35	EGFR-mutated NSCLC after first-line monotherapy or combination therapy	윤성훈 (부산의대)
13:35-14:00	ALK, ROS1, and RET fusion-positive NSCLC after first-line TKI	구강모 (중앙의대)
14:00-14:15	Coffee Break	
14:15-15:05	Session 3: Emerging new therapeutic targets and diagnostic approaches	좌장 최창민 (울산의대)
14:15-14:40	Emerging therapeutic targets in NSCLC	이은혜 (연세의대)
14:40-15:05	Future perspectives on robotic bronchoscopy	이태훈 (울산의대)
15:05-15:20	Coffee Break	
15:20-16:35	Session 4: Management strategies for SCLC after 1st-line chemo-immunotherapy	좌장 오인재 (전남의대)
15:20-15:45	Emerging molecular subtypes and therapeutic implications	정재욱 (충남의대)
15:45-16:10	Tarlatamab and other DLL3-targeted therapy	김미현 (부산의대)
16:10-16:35	Antibody–drug conjugates and novel agents beyond DLL3-targeted therapy	강혜린 (한림의대)
16:35-16:45	숙제보고	손지웅 (건양의대)
16:45-	폐회	